Logo Image

Authors

Kei Muro, MD
Latest Article

Pembrolizumab in Advanced Gastric Cancer Treatment

Kei Muro, MD, discusses phase II and III trials which examine pembrolizumab as a treatment for patients with advanced gastric cancer.

Kelly Davio
Latest Article

Updated Data Support Efficacy of Larotrectinib, Entrectinib in NSCLC

Alexander Drilon, MD,&nbsp;discussed updated findings with larotrectinib in <em>NTRK</em> fusion&ndash;positive tumors and entrectinib in <em>ROS1</em> fusion&ndash;positive NSCLC.<br /> &nbsp;

Kelly Goff, MD
Latest Article

Testing Lesions Improves Diagnosis of Melanoma

Knowledge of genetic expression of melanocytic lesions significantly reduced the number of indeterminate diagnoses made by dermatopathologists.

Kelly Johnson
Latest Article

Link Drawn Between Oral HPV and Risk of Head and Neck Cancers

Patients with a certain type of oral human papilloma virus (HPV) have an increased risk of developing head and neck squamous cell carcinoma, as well as oropharyngeal cancer, according to a new study.

Kelly M. Gaertner
Latest Article

The Potential of ADCs in the Treatment of Breast Cancer

Targeted therapy through the use of antibody drug conjugates holds great promise for the treatment of many malignancies, in particular, breast cancer.

Kelly Ratliff
Latest Article

Collaborative Approach to Specialty Pharmacy Improves Adherence to Oral Oncolytics

The growth of the oncology drug pipeline has fueled the emergence of new oral therapies. While these therapies make treatment more convenient, when compared with traditional infused chemotherapy regimens, they also present new challenges, particularly in the area of adherence.

Kenneth J. Pienta, MD
Kevin B. Kim, MD
Latest Article

The Development of T-VEC for Melanoma

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses the outlook for T-VEC for the treatment of patients with melanoma.

Kevin L. Du, MD, PhD, MSCI
Ki Chung, MD
Kim Farina, PhD
Kim M. Hirshfield MD, PhD
Latest Article

Oncogenic TSHR Mutation in Papillary Thyroid Cancer

We present a case of a 49-year-old woman with a pT4aN1B papillary thyroid cancer who underwent radical thyroidectomy with bilateral neck dissection and RAI I-131 ablation, but poorly tolerated TSH suppression therapy due to tachycardia. Rising thyroglobulin levels and lymph node mapping showed recurrent/progressive disease in the thyroid bed.

Kothai Divya Guruswamy Sangameswaran
Krishnansu S. Tewari, MD, FACOG, FACS
Latest Article

The Impact of CTCs on Survival in Cervical Cancer

Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.

Kristi Rosa
Latest Article

Analysis Highlights rPFS-OS Correlation With Frontline Talazoparib-Enzalutamide in mCRPC

"This [TALAPRO-2] analysis represents the first...patient-level analysis to evaluate rPFS–OS correlation for a PARP inhibitor in first-line mCRPC," said Neeraj Agarwal, MD.

Kristie L. Kahl
Kristie L. Kahl

Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.

She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.

Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.

Latest Article

AI and Biomarkers Refine Risk in HR+/HER2− Early Breast Cancer

AI plus digital pathology and clinical data pinpoint HR+/HER2- early breast cancers with unexpectedly low distant recurrence, sharpening prognosis and guiding endocrine or chemo choices.

Kristin Rojas, MD
Krop Marketing Image.png
Kurt A. Jaeckle, MD
Latest Article

Radiosurgery Versus Radiotherapy Followed by Whole Brain Radiation for Brain Metastases

Kurt Jaeckle, MD, professor of neurology and oncology, Mayo Clinic, discusses radiosurgery versus radiotherapy followed by whole brain radiation for brain metastases.

Kurt Ullman
Latest Article

Bundled Payment: Practice Savior or Killer?

Although there is still disagreement about what it means, the bundling of payments revolves around oncologists being paid a set fee for managing their patients’ care.

Lalitha Priya Chandrashekhar
Latest Article

Targeted Treatments Emerge for HER2 Mutations in Lung Cancer

HER2 mutations have been identified as another oncogenic driver in the growing list of actionable targets in non&ndash;small cell lung cancer. Based on a mounting body of evidence on the impact of HER2 mutations in lung cancer and the growing focus on personalized medicine, the HER2 receptor has gained focus as a potential target for precision medicine treatments for patients with NSCLC.

Lamya Hamad, RPh, MPH
Laura Esserman, MD, MBA
Laura Martin
Latest Article

Reardon on ReACT: First Immunotherapy to Show Benefit in Glioblastoma

Targeted Oncology spoke with David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president of the Society for Neuro-Oncology, and lead author on the ReACT trial to better understand the significance of the study results for patients with glioblastoma.

Laura Panjwani
Latest Article

Expert Discusses Quizartinib Promise in AML

The investigational tyrosine kinase inhibitor quizartinib is extremely promising as a monotherapy for patients with <em>FLT3-ITD&ndash;</em>positive relapsed acute myeloid leukemia.

Lauren Green
Latest Article

Longer Letrozole Treatment Shows Limited Benefit in Early Breast Cancer

Extending treatment with letrozole by an additional 5 years after 5 years of successful treatment did not improve disease-free survival or overall survival in postmenopausal women with early-stage hormone receptor -positive breast cancer.

Lauren M. Green
Latest Article

Web-Based Tool for Symptom Reporting Leads to Longer Survival in Advanced Cancer Patients

Patients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms either while at home or during clinic visits lived on average 5 months longer than their counterparts who had standard symptom monitoring.

Lauren Mays Weddle, PhD
Latest Article

Improving Surveillance for Hepatocellular Carcinoma

Controversy over optimal surveillance methods for hepatocellular carcinoma (HCC) continues to drive ongoing investigation into improved biomarkers and imaging techniques.

Lauren Pinter-Brown, MD
Lauren Schwartz, MD